Call Text Chat Email Refer a Patient Join a Study

Search

MotherToBaby

Medications and More during pregnancy and breastfeeding

Sarilumab (Kevzara®)

Selected References:

  • Cheema R, et al. 2023. Protecting Breastfeeding during the COVID-19 Pandemic. Am J Perinatol. 40(3):260-266.  
  • Dernoncourt A, et al. 2023. Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase®). BioDrugs.37(1):73-87.  
  • Food and Drug Administration. 2025. Kevzara® (sarilumab) Prescribing Information. Available at: https://www.accessdata.fda.gov>label. 
  • Khiali S, et al. 2021. A comprehensive review on sarilumab in COVID-19. Expert Opinion on Biological Therapy; 21(5):615-626.  
  • Krysko KM, et al. 2023. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 22 (4):350-366.  
  • Garcia-Vicuña R, et al. 2020. Subcutaneous Sarilumab in hospitalized patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomized controlled trial. Trials; 21(1):772.  
  • McCarty D, Robinson A. 2018. Efficacy and safety of sarilumab in patients with active rheumatoid arthritis. Ther Adv Musculoskelet Dis; 10(3):61-67.  
  • Mizutani Set al. 2023. A Woman with Rheumatoid Arthritis Who Successfully Delivered a Healthy Child with Continuous Administration of Sarilumab Throughout Pregnancy. Intern Med.62(4):633-636. 
  • Nana M, et al. 2024. Use of interleukin-6 receptor antibodies in the second and third trimester of pregnancy: a retrospective cohort study. Lancet Rheumatol. 6(9):e625-e635.  
  • Prieto-Peña D, et al. 2021. Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. Pol Arch Intern Med; 131(2):171-181.  
  • Raimondo et al. 2017. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drugs Des Devel Ther. 11:1593-1603. 
  • Rüegg L, et al. 2025. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis.84(6):910-926.  
  • Saito J, et al. 2023 Establishment of a measurement system to evaluate breast milk transfer of biological agents using dry filter paper: A multi-institutional study. Br J Clin Pharmacol.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $1,200,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.